Clinical case of coronavirus infection caused by sars-cov-2 virus in a 6 month-old child

Abstract

Introduction: COVID-19-associated lung disease is characterized by typical pathophysiological changes for RDS. Surfactant replacement therapy may be useful in the treatment of patients with COVID-19 associated lung disease; there are a number of studies proving the effectiveness of such therapy in other infections. Administration of exogenous surfactant to patients not included in the neonatal cohort requires further study to determine the dosing regimen and size, but may improve the condition of patients with COVID 19-induced RDS.